Major blood cancer is actually 11 distinct diseases
Discovery could help patients with acute myeloid leukaemia receive far more tailored treatment
One of the most prevalent forms of blood cancer, acute myeloid leukaemia (AML), is actually 11 distinct diseases, say researchers.
Scientists made the discovery after detailed genetic analysis of the disease from 1,540 patients undergoing clinical trials.
"These genetic changes clustered into 11 subtypes which responded differently to the two main treatments for leukaemia: intensive chemotherapy and stem cell transplantation," the Financial Times reports.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
AML is a highly aggressive form of blood cancer and while most patients respond well to chemotherapy in the short term, the relapse rate is particularly high.
"Only 20 per cent survive for five years or more and no new treatments have been introduced for at least 20 years," says Matt Kaiser, of cancer research charity Bloodwise.
Study co-author Peter Campbell, of the Wellcome Trust Sanger Institute, told the BBC the findings could help patients receive a far more tailored treatment regimen.
"I could have two patients who had what looked like the same leukaemia under the microscope and I could treat them with exactly the same therapy," he said. "One of those patients would be cured and one would relapse and die very quickly.
"What we can see in this data-set is that that clinical variability is strongly predicted by the underlying genetics."
Nearly 3,000 people were diagnosed with AML in the UK in 2013, the last year for which figures are available. "While the condition is most common in those over the age of 65, individuals of any age can be affected," says The Guardian.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
Today's political cartoons - November 23, 2024
Cartoons Saturday's cartoons - qualifications, tax cuts, and more
By The Week US Published
-
Long summer days in Iceland's highlands
The Week Recommends While many parts of this volcanic island are barren, there is a 'desolate beauty' to be found in every corner
By The Week UK Published
-
The Democrats: time for wholesale reform?
Talking Point In the 'wreckage' of the election, the party must decide how to rebuild
By The Week UK Published
-
What is sickle cell anaemia?
The Explainer The UK has approved the use of a new drug to treat a disease that predominantly affects people of colour
By Keumars Afifi-Sabet, The Week UK Published
-
Covid might be to blame for an uptick in rare cancers
The explainer The virus may be making us more susceptible to certain cancers
By Devika Rao, The Week US Published
-
The alarming rise of cancer in young people
Under the radar Cancer rates are rising, and the cause is not clear
By Devika Rao, The Week US Published
-
US bans final type of asbestos
Speed Read Exposure to asbestos causes about 40,000 deaths in the U.S. each year
By Peter Weber, The Week US Published
-
'Beyond belief': fears of asbestos return
Under the radar Attention is returning to the dangers of the carcinogenic substance
By Chas Newkey-Burden, The Week UK Published
-
What to say to someone who has cancer
The Explainer Saying something is better than nothing but there are some things to avoid too
By Chas Newkey-Burden, The Week UK Published
-
Anastrozole: the daily breast cancer pill tipped to save thousands of lives
The Explainer Existing treatment approved for preventative use under 'pioneering' NHS drug repurposing scheme
By Harriet Marsden, The Week UK Published
-
The pros and cons of human genetic modification
Pros and Cons Altering human DNA has both a lot of potential and a lot of ethical questions
By Devika Rao, The Week US Published